文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

万古霉素对系统性抗生素暴露期间复发性艰难梭菌感染的二级预防:SPORES-V随机对照试验方案

Secondary Prophylaxis of Recurrent Clostridioides difficile Infections During Systemic Antibiotics with Vancomycin (SPORES-V): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2026-07-09

SPORES-V是一项贝叶斯多中心III期双盲随机对照试验,针对既往120天内患艰难梭菌感染且再次暴露于系统性抗生素的患者,比较预防性口服万古霉素与安慰剂在预防56天复发方面的效果。万古霉素方案为抗生素使用期间125 mg口服每日两次,之后每日一次再用7天。主要结局为意向治疗人群第56天复发,采用校正比值比分析。

要点

  • 艰难梭菌感染约25%的患者治疗后复发,再暴露于系统性抗生素是最强复发危险因素之一。
  • SPORES-V试验评估预防性口服万古霉素在抗生素再暴露期间减少复发的疗效与安全性。
  • 主要结局为第56天复发,采用贝叶斯意向治疗分析并校正比值比。

核心结论

  • SPORES-V试验旨在为万古霉素二级预防复发性艰难梭菌感染的疗效与安全性提供高质量证据。

研究设计与样本

  • SPORES-V为贝叶斯多中心III期双盲随机对照试验,纳入既往120天内患艰难梭菌感染且再次暴露于系统性抗生素的患者。
  • 干预组在抗生素使用期间口服万古霉素125 mg每日两次,之后每日一次再用7天;对照组接受相同日程的安慰剂。
  • 主要结局为第56天艰难梭菌感染复发,按意向治疗使用校正比值比分析。

主要发现

  • 观察性证据和两项小型随机对照试验提示抗生素再暴露期间万古霉素二级预防可能预防复发,但当前证据不明确。

关键数值与推荐

  • 万古霉素方案:抗生素使用期间125 mg口服每日两次,之后每日一次再用7天。
  • 主要结局为第56天复发;次要结局包括不良事件、毒性停药、120天较长复发、56天和120天医疗使用及全因死亡。

临床怎么用

  • 若试验证实有效且安全,预防性口服万古霉素可在艰难梭菌感染史患者再暴露于系统性抗生素时用于减少复发。

局限性

  • 当前证据来自观察性研究和两项小型随机对照试验,尚不能确定万古霉素二级预防的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clostridioides difficile infection (CDI) is a prevalent, morbid, and expensive disease that recurs in approximately 25% of patients despite treatment. Re-exposure to systemic antibiotics is one of the strongest risk factors for recurrence. Observational evidence and two small randomized controlled trials suggest that secondary vancomycin prophylaxis during antibiotic re-exposure may prevent recurrences, but the current evidence is not definitive. METHODS: SPORES-V is a Bayesian multicenter phase III double-blind randomized controlled trial. Patients with CDI in the preceding 120 days who are re-exposed to systemic antibiotics will be randomized to receive prophylactic oral vancomycin (125 mg orally twice daily while on antibiotics and then once daily for 7 days afterwards) or an equal schedule of placebo. The primary outcome is CDI recurrence at day 56, analyzed by intention to treat using an adjusted odds ratio. Secondary outcomes include adverse events, discontinuation due to toxicity, longer-term recurrences (120 days), healthcare usage (56 and 120 days), and all-cause mortality (56 and 120 days). SPORES-V has begun recruitment at the McGill University Health Centre site. DISCUSSION: The SPORES-V trial will provide high-quality evidence on the efficacy and safety of secondary vancomycin prophylaxis in the prevention of recurrent CDI. TRIAL REGISTRATION: ClinicalTrials.gov NCT06979609. Registered on May 13, 2025, https://clinicaltrials.gov/study/NCT06979609 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Prosty C, Carignan A, Chan AK, et al. Secondary Prophylaxis of Recurrent Clostridioides difficile Infections During Systemic Antibiotics with Vancomycin (SPORES-V): study protocol for a randomized controlled trial. Trials. 2026. PMID: 42421140. doi:10.1186/s13063-026-09883-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。